Immunometabolism Drug Development Summit

Memo

As scientific breakthroughs and novel discoveries reveal the causal link and interface between metabolic pathways and immune cell function, the inaugural Immunometabolism Drug Development Summit 2019 is dedicated to help large pharma, biotech and academia translate basic immunometabolism research into a novel class of clinically safe and effective therapeutics for immune-mediated diseases. The field of immunometabolism has thrived over the last decade, revealing not only a better understanding of immune cells and their functions but also the impact of key metabolic pathways on immune cell development, fate, and behavior. As such the emerging field of immunometabolism offers a tremendous opportunity to set a higher standard for how immune-mediated diseases are treated. http://www.immunometabolismdrugdev.com/ Contact:This email address is being protected from spambots. You need JavaScript enabled to view it.+ 1 617 455 4188 URLs:Brochure:  https://go.evvnt.com/304815-0?pid=5569Tickets:  https://go.evvnt.com/304815-1?pid=5569 Time: 8:00 am to 4:00 pm, Venue details: The Colonnade Boston Hotel, 120 Huntington Avenue, Boston, 02116, United States, Prices:Drug Developer and Solution Provider Earlybird Conference + 1 Workshop (Book by 09/11/18): USD 1798.0,Drug Developer and Solution Provider Conference + 1 Workshop (standard rate) : USD 2398.0,Academic, Not-for-Profit and Start-up* Earlybird Conference + 1 Workshop (Book by 09/11/18): USD 1298.0,Academic, Not-for-Profit and Start-up* Conference + 1 Workshop (standard rate): USD 1898.0,Drug Developer and Solution Provider Conference Only Earlybird (Book by 09/11/18): USD 1399.0,Drug Developer and Solution Provider Conference Only (standard rate): USD 1999.0,Academic, Not-for-Profit and Start-up* Conference Only Earlybird (Book by 09/11/18): USD 899.0,Academic, Not-for-Profit and Start-up* Conference Only (standard rate): USD 1499.0, Speakers: Laurence Turka (Rheos Medicines), Robert Wild (Dracen Pharmaceuticals), Paul-Peter Tak (Levicept and Sitryx Therapeutics), Lauriane Cabon (Roche), Mateusz Nowak (Selvita)